Ibrutinib with R-CHOP for untreated mantle cell lymphoma
KSR acted as the External Assessment Group (EAG) for NICE on a technology appraisal published today (23.9.26): Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [TA1193].
“We welcome the approval of ibrutinib in combination with chemo-immunotherapy as an important treatment option for people with mantle cell lymphoma”, said Anna Grint, Patient and Public Affairs at Lymphoma Action. “Throughout the NICE appraisal, we worked closely with people affected by mantle cell lymphoma to ensure that their experiences and priorities were heard. For many patients, the prospect of a stem cell transplant can be one of the most challenging aspects of treatment. Having access to an effective alternative that may potentially eliminate the need for a transplant means fewer side effects, a faster recovery, and less disruption to daily life. This decision represents a significant step forward and gives people affected by mantle cell lymphoma greater choice in their treatment.” [Oncology News Today; 7.9.26]
Further information can be found on the NICE website.
Photo by National Cancer Institute on Unsplash
